However, triple negative-breast cancer (TNBC), which is characterized by the lack of an estrogen receptor (ER), progesterone receptor (PR), and Her2 overexpression, could not benefit from both endocrine therapy and Her2-targeted therapy (Agrawal and Mayer, 2014). The gene discussed is ESR1; the disease is triple-negative breast carcinoma.